Immunisation body likely to consider Corbevax as booster for those jabbed with Covishield, Covaxin 

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above.

published on : 27th June 2022

DCGI to review Serum Institute's applications for Covovax use in kids aged 2 to 7 yrs, 7 to 11 yrs 

The expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years.

published on : 23rd June 2022

‘Covaxin booster improves efficacy against two variants’: Bharat Biotech

A booster dose of Covaxin enhances vaccine effectiveness against Delta and Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said. 

published on : 16th June 2022

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, find ICMR study

The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer reviewed.

published on : 15th June 2022

NTAGI to discuss allowing Corbevax as booster for those vaccinated with Covishield, Covaxin: Sources

The Drugs Controller General of India (DCGI) on Sunday approved Corbevax for the precaution dose for those aged 18 and above.

published on : 7th June 2022

Germany to recognise Covaxin for travel purpose from June 1, says envoy

In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin.

published on : 26th May 2022

FDA lifts hold on Covaxin's clinical trials in US

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab.

published on : 24th May 2022

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.

published on : 4th May 2022

Bharat Biotech's Covaxin gets emergency approval for 6-12 age group

The company said it conducted clinical trials in the paediatric population between June 2021 to September 2021 and results have shown robust safety, reactogenicity, and immunogenicity.

published on : 26th April 2022

Covid-19: Three vaccines for children get emergency use approval from drug controller

The new approvals were tweeted by Union Health Minister Dr Mansukh Mandaviya, who said that India's fight against Covid has become more robust.

published on : 26th April 2022

Ocugen to commercialise Covaxin in Mexico

City-based pharma major Bharat Biotech’s US partner Ocugen, Inc. has got the permission to commercialise  Covid vaccine Covaxin in Mexico.

published on : 19th April 2022

Bharat Biotech expands Covaxin pact with Ocugen to enter North America market

The Hyderabad-based pharma major has also sought EUA for use of Covaxin for children in the 2-18 years age group in Mexico.

published on : 18th April 2022

Covaxin's phase 2/3 clinical trials put on hold in the US

The WHO had earlier suspended supply through UN agencies of Coavaxin after inspectors identified good manufacturing practice deficiencies in the company's pharma plant.

published on : 14th April 2022

US FDA puts Covaxin's second phase trials in US on hold after fallout on WHO's observations

WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP deficiencies in the Bharat Biotech's manufacturing plants.

published on : 14th April 2022

Covishield & Covaxin prices cut, hospitals to pay Rs 225 per dose

The precautionary dose has to be of the same vaccine used for the first two doses.

published on : 10th April 2022
1 2 3 4 5 6 >